PersoMed-I: This study evaluating whether personalised risk-adapted treatment (including radiation therapy, targeted therapy and chemotherapy) improves outcomes for people post-puberty with newly-diagnosed medulloblastomaPersonalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma (PersoMed-I)

Summary

This study is recruiting people with any standard risk medulloblastoma, including those with SHH Subtype medulloblastoma. Eligible participants will be assigned into cohorts based on their medulloblastoma subtype. Within each cohort, participants will be randomly allocated to receive either the standard treatment or the experimental treatment. Those in the standard (control) arm will receive radiation therapy plus standard chemotherapy (cisplatin, lomustine and vincristine). In the Experimental Arm, participants will receive experimental doses of radiation therapy plus standard chemotherapy (cisplatin, lomustine and vincristine). For those patients with SHH subtype medulloblastoma who are allocated to receive experimental treatment, they will also be treated with targeted therapy (sonidegib) in addition to radiation therapy and chemotherapy.